EGFR and non-small cell lung carcinoma: Besides, there were two types of drug: amivantamab(mOS = 22.8 mth) and mobocertinib (mOS = 24 mth), receiving Accelerated Approval from the FDA for the treatment of advanced-stage non-small-cell lung cancer patients with EGFR exon 20 INs in 2021, which brought new choice for young lung cancer patients.